Uterine Cancer - Pipeline Review, H2 2014

Date: September 10, 2014
Pages: 66
Price:
US$ 2,000.00 US$ 1,500.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: U262D819705EN
Leaflet:

Download PDF Leaflet

Uterine Cancer - Pipeline Review, H2 2014

SUMMARY

Global Markets Direct’s, ‘Uterine Cancer - Pipeline Review, H2 2014’, provides an overview of the Uterine Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Uterine Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uterine Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Uterine Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Uterine Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Uterine Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Uterine Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Uterine Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Uterine Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Uterine Cancer Overview
Therapeutics Development
Pipeline Products for Uterine Cancer - Overview
Pipeline Products for Uterine Cancer - Comparative Analysis
Uterine Cancer - Therapeutics under Development by Companies
Uterine Cancer - Therapeutics under Investigation by Universities/Institutes
Uterine Cancer - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Uterine Cancer - Products under Development by Companies
Uterine Cancer - Products under Investigation by Universities/Institutes
Uterine Cancer - Companies Involved in Therapeutics Development
GlaxoSmithKline plc
Azaya Therapeutics Incorporated
EndoCeutics, Inc.
Karyopharm Therapeutics, Inc.
Uterine Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
acolbifene hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peptide to Target COX-2 and MAS-GPCR for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pazopanib hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
selinexor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
docetaxel liposomal - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MVX-ONCO-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Adva-27a - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit GARFT for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Uterine Cancer - Recent Pipeline Updates
Uterine Cancer - Dormant Projects
Uterine Cancer - Product Development Milestones
Featured News & Press Releases
Jun 09, 2014: Sunshine Biopharma's Adva-27a Featured in 2014 Worldwide Uterine Cancer Report for Its Effectiveness Against Multidrug Resistant Uterine Cancer Cells
Aug 12, 2013: Advanomics wins research grant for cancer drug candidate
Jun 19, 2013: Sunshine Biopharma's Anticancer Drug Candidate Adva-27a Is Unaffected By Recent Supreme Court Ruling On Patentability Of Human Genes
Jan 15, 2013: Advanomics Files New Patent Application For Multidrug Resistance Adva-27a Anticancer Compound
Dec 10, 2012: Sunshine Biopharma Completes Another IND-enabling Study Of Adva-27a
Jun 13, 2012: Azaya Therapeutics Reports Phase I Clinical Trial Results Of ATI-1123
May 29, 2012: Immunovaccine To Present Clinical Data On DPX-0907 Cancer Vaccine At 2012 ASCO Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Uterine Cancer, H2 2014
Number of Products under Development for Uterine Cancer - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Number of Products under Investigation by Universities/Institutes, H2 2014
Comparative Analysis by Late Stage Development, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Development, H2 2014
Products under Development by Companies, H2 2014
Products under Investigation by Universities/Institutes, H2 2014
Uterine Cancer - Pipeline by GlaxoSmithKline plc, H2 2014
Uterine Cancer - Pipeline by Azaya Therapeutics Incorporated, H2 2014
Uterine Cancer - Pipeline by EndoCeutics, Inc., H2 2014
Uterine Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Stage and Target, H2 2014
Number of Products by Stage and Mechanism of Action, H2 2014
Number of Products by Stage and Route of Administration, H2 2014
Number of Products by Stage and Molecule Type, H2 2014
Uterine Cancer Therapeutics - Recent Pipeline Updates, H2 2014
Uterine Cancer - Dormant Projects, H2 2014

LIST OF FIGURES

Number of Products under Development for Uterine Cancer, H2 2014
Number of Products under Development for Uterine Cancer - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Number of Products under Investigation by Universities/Institutes, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Products, H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Top 10 Target, H2 2014
Number of Products by Stage and Top 10 Target, H2 2014
Number of Products by Top 10 Mechanism of Action, H2 2014
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014
Number of Products by Top 10 Route of Administration, H2 2014
Number of Products by Stage and Top 10 Route of Administration, H2 2014
Number of Products by Top 10 Molecule Type, H2 2014
Number of Products by Stage and Top 10 Molecule Type, H2 2014

COMPANIES MENTIONED

GlaxoSmithKline plc
Azaya Therapeutics Incorporated
EndoCeutics, Inc.
Karyopharm Therapeutics, Inc.
Skip to top


Ask Your Question

Uterine Cancer - Pipeline Review, H2 2014
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: